Clinical Trial Update: Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sunitinib with transarterial chemoembolization for unresectable liver cancer; the trial was terminated and results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Liver Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-06-04